Table 1.
Total Comments, Sentiments, and Rates of Categories From 2011 to 2015 for Infliximab
| Year | Total number of comments | Total number of coded sentiments | Sentiments |
|||||
|---|---|---|---|---|---|---|---|---|
| Positive experience/supportive comment | Negative experience/adverse side-effect | Cost | Loss of efficacy | Diet | Infusion-related | |||
| 2011 | 156 | 160 | 37.5% | 28.1% | 13.1% | 6.9% | 1.3% | 13.1% |
| 2012 | 380 | 357 | 36.1% | 26.6% | 14.6% | 8.1% | 5.6% | 9.0% |
| 2013 | 296 | 282 | 40.4% | 28.0% | 5.3% | 5.7% | 2.8% | 17.7% |
| 2014 | 457 | 356 | 37.4% | 25.0% | 24.7% | 4.2% | 1.4% | 7.3% |
| 2015 | 477 | 306 | 50.3% | 20.6% | 11.1% | 8.2% | 4.6% | 5.2% |
| Spearman’s rho, P-value | rho 0.90, P = .04 | rho 0.30, P = .62 | rho = 0.50, P = .39 | rho = -0.90, P = .04 | rho = −0.10, P = .87 | rho = −0.10, P = .87 | rho = −0.30, P = .87 | rho = −0.70, P = .19 |